Brief: Basilea Announces Approval For Additional Formulation Of Antifungal Cresemba In China

Basilea Pharmaceutica AG, Allschwil

24/06/2022 06:16

June 24 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * BASILEA ANNOUNCES APPROVAL FOR ADDITIONAL FORMULATION OF
ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) IN CHINA
    * CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)
GRANTED
DRUG APPROVAL LICENSE TO BASILEA'S LICENSE PARTNER, PFIZER INC.
    * INTRAVENOUS USE OF CRESEMBA APPROVED FOR TREATMENT OF
ADULT
PATIENTS WITH INVASIVE ASPERGILLOSIS AND INVASIVE MUCORMYCOSIS
FOLLOWING PREVIOUS APPROVAL OF ORAL DOSAGE FORM
    * THIS IS SECOND APPROVED FORMULATION FOR CRESEMBA IN CHINA,
IN
ADDITION TO ORAL FORMULATION FOR INVASIVE ASPERGILLOSIS AND
INVASIVE MUCORMYCOSIS
    * ANNOUNCED TODAY THAT ITS LICENSE PARTNER, PFIZER INC.
(NYSE:
PFE, "PFIZER"), HAS RECEIVED A DRUG APPROVAL LICENSE FROM
NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA

Source text for Eikon:  ID:nGNEbH7ydc 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))